Title | Opposing role of phagocytic receptors MERTK and AXL in Progranulin deficient FTD. |
Publication Type | Journal Article |
Year of Publication | 2025 |
Authors | Clelland CDudley, Fan L, Saloner R, Etchegaray JIker, Altobelli CRichard, Salomonsson S, Maltos AM, Sachdev A, Zhu J, Lee S-I, Li Y, Zhou Y, Le D, Wang C, Carling G, Kodama L, Sayed F, Perez-Bermejo JA, Geier EG, Yokoyama JS, Rosen H, Nana AL, Spina S, Grinberg LT, Seeley WW, Elahi F, Boxer AL, Arkin MR, Gan L |
Journal | Commun Biol |
Volume | 8 |
Issue | 1 |
Pagination | 971 |
Date Published | 2025 Jul 01 |
ISSN | 2399-3642 |
Keywords | Animals, Axl Receptor Tyrosine Kinase, c-Mer Tyrosine Kinase, Female, Frontotemporal Dementia, Humans, Male, Mice, Mice, Knockout, Microglia, Mutation, Phagocytosis, Progranulins, Proto-Oncogene Proteins, Receptor Protein-Tyrosine Kinases |
Abstract | Genetic mutations in the progranulin gene, GRN, cause frontotemporal dementia and a lysosomal storage disorder. Using single-nuclei RNA sequencing of the post-mortem brain tissue from adult heterozygous pathogenic granulin variant (GRN+/-) carriers we find dysregulation of microglia, phagocytosis and the phagocytic receptors MERTK and AXL. Exogenous progranulin regulates MERTK and AXL RNA expression in human microglia induced from iPSCs irrespective of GRN mutation status, without directly binding to MERTK or AXL proteins. We generated double knock-out mice and find that constitutive homozygous loss of Grn and Mertk (Grn-/-;Mertk-/-) rescued microglial disease signature while constitutive homozygous loss of Grn and Axl (Grn-/-;Axl-/-) worsened the microglial disease signature and increased lipofuscin. Lower CSF MERTK but not AXL is associated with lower progranulin levels. Furthermore, CSF MERTK is lower in symptomatic but not presymptomatic FTD patients with genetic mutations (GRN, C9ORF72, and MAPT) whereas AXL does not change between disease state and control. These data explain in part the inflammation seen in GRN-FTD and are applicable to other inflammatory states in which PGRN, MERTK and AXL play regulatory roles beyond neurodegenerative diseases. The interaction between GRN, MERTK, and AXL opens potential new therapeutic avenues to intervene on this inflammatory axis. |
DOI | 10.1038/s42003-025-08368-2 |
Alternate Journal | Commun Biol |
PubMed ID | 40596721 |
PubMed Central ID | PMC12218935 |
Grant List | U54 NS100717 / NS / NINDS NIH HHS / United States U24 AG021886 / AG / NIA NIH HHS / United States U01 AG057195 / AG / NIA NIH HHS / United States U19 AG063911 / AG / NIA NIH HHS / United States K08 NS112330 / NS / NINDS NIH HHS / United States R01 AG074541 / AG / NIA NIH HHS / United States P30 AG062422 / AG / NIA NIH HHS / United States P01 AG019724 / AG / NIA NIH HHS / United States TL1 TR001871 / TR / NCATS NIH HHS / United States R01 AG072758 / AG / NIA NIH HHS / United States R01 AG054214 / AG / NIA NIH HHS / United States U01 AG045390 / AG / NIA NIH HHS / United States U54 NS092089 / NS / NINDS NIH HHS / United States |